Haloperidol
- PDF / 169,795 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 6 Downloads / 164 Views
1 S
Neuroleptic malignant syndrome: case report A 51-year-old man developed neuroleptic malignant syndrome (NMS) during treatment with haloperidol for delirium. The man presented with traumatic amputation of bilateral lower limbs following a suicide attempt on the railway tracks. Following presentation, he underwent emergency amputation. Post surgery, he developed depression and exhibited non-compliance to treatment. For delirium, he was started on haloperidol [route and dosage not stated]. Ten days after the surgery, he developed sepsis at the stump of the right leg and was scheduled for debridement. At the time, he appeared agitated and restless. Additionally, he was sweating and had a HR 140 bpm associated with hypertension. During examination, he was found to have rigidity. Following investigations, he was found to have creatinine phosphokinase (CPK) level 1 200 U/L, haemoglobin 7 gm%, potassium 5.5 meq/L and leukocyte count 15 000 /mm3. Based on these results, a provisional diagnosis of NMS was made and haloperidol was considered as a culprit. Therefore, haloperidol was discontinued and the man was treated with bromocriptine. Following which, his symptoms subsided and CPK levels gradually improved (125 U/L). This affirmed the diagnosis of NMS, which he developed following haloperidol therapy for duration of five days. Thereafter, debridement of amputated stump was performed uneventfully and on third postoperative day, he was discharged. Chauhan R, et al. Importance of preanesthetic evaluation in emergency: Are we in haste. Journal of Anaesthesiology Clinical Pharmacology 36: 273-274, No. 2, Apr-Jun 2020. 803508336 Available from: URL: http://doi.org/10.4103/joacp.JOACP_216_19
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
